|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.85 HKD | +0.72% |
|
-2.26% | -13.32% |
| 18/06 | Sinopharm Group Co. Ltd. Approves Ordinary Final Dividend for the Year Ended 31 December 2025, Payable on 18 August 2026 | CI |
| 27/04 | Earnings Season, Tehran Proposal Lift Asian Stock Markets | MT |
Business description: Sinopharm Group Co. Ltd.
Number of employees: 94,910
Sales by Activity: Sinopharm Group Co. Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
Pharmaceutical Distribution | 39TCr | 41TCr | 44TCr | 44TCr | 44TCr |
Medical Devices | 11TCr | 12TCr | 13TCr | 12TCr | 12TCr |
Other Business | 982.1Cr | 1.02TCr | 1.04TCr | 910.65Cr | 885.29Cr |
Retail Pharmacy | 2.91TCr | 3.3TCr | 3.57TCr | 3.6TCr | 3.84TCr |
Eliminations | -1.59TCr | -1.85TCr | -2.08TCr | -2.29TCr | -2.3TCr |
Geographical breakdown of sales: Sinopharm Group Co. Ltd.
| Fiscal Period: December | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|
People's Republic of China (PRC) | 52TCr | 55TCr | 60TCr | 58TCr | 58TCr |
Executive Committee: Sinopharm Group Co. Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
Wan Yong Lian
PSD | President | 56 | 27/08/2024 |
Ligang Hu
PRN | Corporate Officer/Principal | 51 | 09/06/2025 |
Yi Jian Wu
SEC | Corporate Secretary | 56 | - |
Xiu Chang Jiang
DFI | Director of Finance/CFO | 62 | 01/05/2010 |
Shuang Jun Xu
PRN | Corporate Officer/Principal | 57 | 01/03/2011 |
Composition of the Board of Directors: Sinopharm Group Co. Ltd.
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 54 | 01/05/2010 |
Zheng Dong Liu
BRD | Director/Board Member | 56 | 21/09/2014 |
De Yong Wen
BRD | Director/Board Member | 54 | 01/09/2017 |
Xiao Hui Guan
CHM | Chairman | 55 | - |
Tak Lung Wu
BRD | Director/Board Member | 60 | 18/09/2020 |
Wei Feng Yu
BRD | Director/Board Member | 63 | 18/09/2020 |
Hai Qing Lu
BRD | Director/Board Member | 52 | 18/09/2020 |
Pei Yu Li
BRD | Director/Board Member | 63 | 18/09/2020 |
Sheng Hao Shi
BRD | Director/Board Member | 57 | 15/06/2023 |
Jinhong Guo
BRD | Director/Board Member | 53 | 25/08/2023 |
Company details: Sinopharm Group Co. Ltd.
Sinopharm Group Co., Ltd.
Sinopharm Group Building
200023, Shanghai
+86 21 2305 2666
http://ir.sinopharmgroup.com.cn
Pharmaceuticals Wholesale
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.72% | -2.26% | -11.96% | -27.99% | 665.93Cr | |
| +1.66% | +2.50% | +13.58% | +97.17% | 9.44TCr | |
| +0.87% | -1.31% | +46.49% | +152.00% | 5.52TCr | |
| +3.55% | +3.55% | +3.91% | +269.62% | 2.26TCr | |
| +0.37% | +0.06% | -15.11% | -23.30% | 801.29Cr | |
| +1.98% | -2.23% | -26.79% | -34.74% | 759.91Cr | |
| -1.39% | -2.14% | +21.75% | +35.54% | 625.25Cr | |
| -0.09% | +0.99% | -2.36% | +23.02% | 535.73Cr | |
| +0.20% | +1.42% | -6.18% | -7.01% | 368.44Cr | |
| +0.95% | -1.46% | +10.88% | +16.56% | 334.06Cr | |
| Average | +0.88% | -0.54% | +3.42% | +50.09% | 2.13TCr | |
| Weighted average by Cap. | +1.42% | +0.63% | +17.22% | +109.76% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 1099 Stock
- Company Sinopharm Group Co. Ltd.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition